Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist (Q37033865)

17 August 2017

1 reference

title

Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist (English)

1 reference

17 August 2017

1 reference

Frances McManus

1

1 reference

17 August 2017

Gordon T McInnes

series ordinal

2

1 reference

17 August 2017

John M C Connell

series ordinal

3

1 reference

17 August 2017

publication date

1 January 2008

1 reference

Nature Clinical Practice Endocrinology and Metabolism

17 August 2017

published in

1 reference

17 August 2017

volume

4

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

44-52

1 reference

Aldosterone induces a vascular inflammatory phenotype in the rat heart

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

Changes in left ventricular anatomy and function in hypertension and primary aldosteronism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

Mineralocorticoid receptors and hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

A quick glance at rapid aldosterone action

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Local renin-angiotensin systems and their interactions with extra-adrenal corticosteroid production

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

The new biology of aldosterone

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

The mineralocorticoid receptor mediates aldosterone-induced differentiation of T37i cells into brown adipocytes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

RALES, EPHESUS and redox

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Potentially high prevalence of primary aldosteronism in a primary-care population

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Hyperaldosteronism among black and white subjects with resistant hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Serum aldosterone and the incidence of hypertension in nonhypertensive persons

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Remodeling of the rat right and left ventricles in experimental hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Aldosterone: a mediator of myocardial necrosis and renal arteriopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Efficacy and tolerance of spironolactone in essential hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Effect of spironolactone on blood pressure in subjects with resistant hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Efficacy of low-dose spironolactone in subjects with resistant hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Low-dose spironolactone in the management of resistant hypertension: a surveillance study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Antialdosterones: incidence and prevention of sexual side effects

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Mineralocorticoid receptor antagonism in experimental atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Eplerenone inhibits atherosclerosis in nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Mineralocorticoid Receptor Antagonist Reduces Renal Injury in Rodent Models of Types 1 and 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Effects of eplerenone versus losartan in patients with low-renin hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Can Renin Status Predict the Antihypertensive Efficacy of Eplerenone Add‐On Therapy?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0676

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0676

1 reference

17 August 2017

1 reference